Seminars in Nephrology
Volume 27, Issue 2 , Pages 144-152 , March 2007

The Renin-Angiotensin System and Diabetic Nephropathy

  • Susan B. Gurley, MD, PhD
    • ,
  • Thomas M. Coffman, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Thomas M. Coffman, MD, Building 6/Nephrology (111I), VA Medical Center, 508 Fulton St, Durham, NC 27705.

References 

  1. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev. 1977;57:313–370
  2. Bock HA, Hermle M, Brunner FP, et al. Pressure dependent modulation of renin release in isolated perfused glomeruli. Kidney Int. 1992;41:275–280
  3. Carey RM, McGrath HE, Pentz ES, et al. Biomechanical coupling in renin-releasing cells. J Clin Invest. 1997;100:1566–1574
  4. Bell PD, Lapointe JY, Sabirov R, et al. Macula densa cell signaling involves ATP release through a maxi anion channel. Proc Natl Acad Sci U S A. 2003;100:4322–4327
  5. Lorenz JN, Weihprecht H, He XR, et al. Effects of adenosine and angiotensin on macula densa-stimulated renin secretion. Am J Physiol. 1993;265:F187–F194
  6. Admiraal PJ, van Kesteren CA, Danser AH, et al. Uptake and proteolytic activation of prorenin by cultured human endothelial cells. J Hypertens. 1999;17:621–629
  7. Beldent V, Michaud A, Wei L, et al. Proteolytic release of human angiotensin-converting enzyme (Localization of the cleavage site). J Biol Chem. 1993;268:26428–26434
  8. Margolius HS. Kallikreins and kinins (Molecular characteristics and cellular and tissue responses). Diabetes. 1996;45(Suppl 1):S14–S19
  9. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285–1292
  10. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205–251
  11. Gurley SB, Le TH, Coffman TM. Gene-targeting studies of the renin-angiotensin system: mechanisms of hypertension and cardiovascular disease. Cold Spring Harb Symp Quant Biol. 2002;67:451–457
  12. Hein L, Stevens ME, Barsh GS, Pratt RE, et al. Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci U S A. 1997;94:6391–6396
  13. Ichiki T, Labosky PA, Shiota C. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 1995;377:748–750
  14. Masaki H, Kurihara T, Yamaki A, et al. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest. 1998;101:527–535
  15. Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int. 1981;19:410–415
  16. Zatz R, Meyer TW, Rennke HG, et al. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A. 1985;82:5963–5967
  17. Zatz R, Dunn BR, Meyer TW, Anderson S, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925–1930
  18. Anderson S, Meyer TW, Rennke HG, et al. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985;76:612–619
  19. Yamamoto T, Nakamura T, Noble NA, et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A. 1993;90:1814–1818
  20. Kagami S, Border WA, Miller DE, et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994;93:2431–2437
  21. Yamamoto T, Noble NA, Cohen AH, et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int. 1996;49:461–469
  22. Yu L, Border WA, Huang Y, et al. TGF-beta isoforms in renal fibrogenesis. Kidney Int. 2003;64:844–856
  23. Mozes MM, Bottinger EP, Jacot TA. Renal expression of fibrotic matrix proteins and of transforming growth factor-β (TGF-β) isoforms in TGF-β transgenic mice. J Am Soc Nephrol. 1999;10:271–280
  24. Lewis EJ, Hunsicker LG, Bain RP, et al. The Collaborative Study Group The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462
  25. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  26. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  27. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878
  28. US Renal Data System. USRDS 2006 annual data report (atlas of end-stage renal disease in the United States). Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;
  29. Pettitt DJ, Saad MF, Bennett PH, et al. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:438–443
  30. Cowie CC. Diabetic renal disease: racial and ethnic differences from an epidemiologic perspective. Transplant Proc. 1993;25:2426–2430
  31. Krolewski AS. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int. 1999;55:1582–1596
  32. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–1346
  33. Huang W, Gallois Y, Bouby N, et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci U S A. 2001;98:13330–13334
  34. Takahashi N, Hagaman JR, Kim HS, et al. Minireview: computer simulations of blood pressure regulation by the renin-angiotensin system. Endocrinology. 2003;144:2184–2190
  35. Kakoki M, Takahashi N, Jennette JC, et al. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci U S A. 2004;101:13302–13305
  36. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1–E9
  37. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme (Cloning and functional expression as a captopril-insensitive carboxypeptidase). J Biol Chem. 2000;275:33238–33243
  38. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838–14843
  39. Ferrario CM, Brosnihan KB, Diz DI, et al. Angiotensin-(1-7): a new hormone of the angiotensin system. Hypertension. 1991;18:126–133
  40. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258–8263
  41. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol. 2005;289:H2281–H2290
  42. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–828
  43. Yamamoto K, Ohishi M, Katsuya T, et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension. 2006;47:718–726
  44. Gurley SB, Allred A, Le TH, et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest. 2006;116:2218–2225
  45. Zhang H, Wada J, Hida K, et al. Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J Biol Chem. 2001;276:17132–17139
  46. Malakauskas SM, Quan H, Fields TA, et al. Aminoaciduria and altered renal expression of luminal amino acid transporters in mice lacking novel gene collectrin. Am J Physiol. Epub. 2006;Accession number: 16985211
  47. Tikellis C, Johnston CI, Forbes JM, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension. 2003;41:392–397
  48. Ye M, Wysocki J, Naaz P, et al. Increased ACE2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination. Hypertension. 2004;43:1120–1125
  49. Wysocki J, Ye M, Soler MJ, et al. ACE and ACE2 activity in diabetic mice. Diabetes. 2006;55:2132–2139
  50. Trujillo A, Eggena P, Barrett J, et al. Renin regulation in type II diabetes mellitus: influence of dietary sodium. Hypertension. 1989;13:200–205
  51. Tuck ML, Sambhi MP, Levin L. Hyporeninemic hypoaldosteronism in diabetes mellitus (Studies of the autonomic nervous system’s control of rennin release). Diabetes. 1979;28:237–241
  52. Burden AC, Thurston H. Plasma rennin activity in diabetes mellitus. Clin Sci (Lond). 1979;56:255–259
  53. Rudberg S, Persson B, Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy: an 8-year prospective study. Kidney Int. 1992;41:822
  54. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747–803
  55. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical and molecular biological correlations. Am J Physiol. 1993;265:4777–4786
  56. Lafayette RA, Mayer G, Park SK, et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1992;90:766–771
  57. Yasuda T, Kondo S, Homma T, et al. Regulation of extracellular matrix by mechanical stress in rat glomerular mesangial cells. J Clin Invest. 1996;98:1991–2000
  58. Cortes P, Zhao X, Riser BL, et al. Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy. Kidney Int. 1997;51:57–68
  59. Durvasula RV, Petermann AT, Hiromura K, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 2004;65:30–39
  60. Doublier S, Salvidio G, Lupia E, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes. 2003;52:1023–1030
  61. Bonnet F, Cooper ME, Kawachi H, et al. Irbesartan normalizes the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia. 2001;44:874–877
  62. Langham RG, Kelly DJ, Cox AJ, et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia. 2002;45:1572–1576
  63. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures (A HOPE substudy). Hypertension. 2001;38:e28
  64. Griffin KA, Abu-Amarah I, Picken M, et al. Renoprotection by ACE inhibition or aldosterone blockade is blood pressure–dependent. Hypertension. 2003;41:201–206
  65. Breyer MD, Bottinger E, Brosius FC, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16:27–45

 Supported in part by grants from the National Institutes of Health (5 U01 HL070523-05), the American Heart Association, and the US Department of Veterans Affairs.

PII: S0270-9295(07)00010-1

doi: 10.1016/j.semnephrol.2007.01.009

Seminars in Nephrology
Volume 27, Issue 2 , Pages 144-152 , March 2007

Article Tools

* Image Usage & Resolution